title: Feasibility and diagnostic accuracy of a gated SPECT early-imaging protocol: a multicenter study of the Myoview Imaging Optimization Group.
abstract: The aim of this study was to investigate whether early (time 1, or T1) myocardial tetrofosmin imaging is feasible and as accurate in detecting coronary artery disease as is standard delayed (time 2, or T2) imaging.
  
  
  METHODS
  One hundred twenty patients (100 men and 20 women; mean age +/- SD, 61 +/- 10 y) with anginal symptoms underwent tetrofosmin gated SPECT. Stress/rest T1 imaging was performed at 15 min and T2 at 45 min after injection. Image quality was visually evaluated using a 4-point scale (from 0 = poor to 3 = optimal). Myocardial perfusion analysis was performed on a 20-segment model using quantitative perfusion SPECT software, and reversible ischemia was scored as a summed difference score (SDS). Coronary angiography was performed within 1 mo on all patients, and stenosis of more than 50% of the diameter was considered significant.
  
  
  RESULTS
  Overall, quality was scored as optimal or good for 94% of T1 images and 95% of T2 images (P = not statistically significant). Heart, lung, liver, and subdiaphragmatic counts did not differ for stress and rest T1 and T2 imaging. A good linear relationship was seen between T1 and T2 SDS (r = 0.69; P < 0.0001), and Bland-Altman analysis showed good agreement between the 2 conditions. In terms of global diagnostic accuracy, areas under the receiver-operating-characteristic curve were comparable between T1 and T2 (0.80 vs. 0.81, P = not statistically significant). Discrepancies between T1 and T2 SDS were observed in 44% of patients (T1 - T2 SDS > 2). Linear regression analysis showed a good correlation between T1 and T2 SDS (r = 0.67; P < 0.0001), whereas the Bland-Altman method showed a shift in the mean value of the difference of +2.67 +/- 2.73. In patients with a T1 - T2 SDS of more than 2, areas under the receiver-operating-characteristic curves were significantly higher for T1 than for T2 images (0.79 vs. 0.70, P < 0.001).
  
  
  CONCLUSIONS
  T1 imaging is feasible and as accurate as T2 imaging in identifying coronary artery disease. However, in a discrete subset of patients, early acquisition strengthens the clinical message of defect reversibility by permitting earlier, more accurate identification of more severe myocardial ischemia.
authors.affiliation: CNR Institute of Clinical Physiology, Pisa, Italy. asso@ifc.cnr.it
authors.forename: Assuero
authors.initials: A
authors.lastname: Giorgetti
authors.forename: Massimiliano
authors.initials: M
authors.lastname: Rossi
authors.forename: Mario
authors.initials: M
authors.lastname: Stanislao
authors.forename: Guido
authors.initials: G
authors.lastname: Valle
authors.forename: Pietro
authors.initials: P
authors.lastname: Bertolaccini
authors.forename: Alberto
authors.initials: A
authors.lastname: Maneschi
authors.forename: Raffaele
authors.initials: R
authors.lastname: Giubbini
authors.forename: Maria Luisa
authors.initials: ML
authors.lastname: De Rimini
authors.forename: Marco
authors.initials: M
authors.lastname: Mazzanti
authors.forename: Mario
authors.initials: M
authors.lastname: Cappagli
authors.forename: Elisa
authors.initials: E
authors.lastname: Milan
authors.forename: Duccio
authors.initials: D
authors.lastname: Volterrani
authors.forename: Paolo
authors.initials: P
authors.lastname: Marzullo
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging*; D005240:Feasibility Studies; D005260:Female; D015637:Gated Blood-Pool Imaging / Q000379:methods*; D006801:Humans; D007558:Italy; D008297:Male; D009943:Organophosphorus Compounds; D015609:Organotechnetium Compounds; D011379:Prognosis; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D018570:Risk Assessment / Q000379:methods; D012307:Risk Factors; D012680:Sensitivity and Specificity; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods*
chemical_list: D009943:Organophosphorus Compounds; D015609:Organotechnetium Compounds; D019275:Radiopharmaceuticals; C078700:technetium tc-99m tetrofosmin